Recent developments in the use of chemotherapy in brain tumours

Bent, Martin J. van den; Hegi, Monika E.; Stupp, Roger

doi:10.1016/j.ejca.2005.06.031

Cited by 109 publications

(68 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An additional complication is that radiologic imaging mostly fails to properly delineate tumor margins because blood vessels in the infiltrative parts generally display an intact BBB, precluding extravasation of magnetic resonance contrast agents (19). Temozolomide is currently the chemotherapy of choice for high-grade astrocytomas and oligodendrogliomas adjuvant to surgery and/or radiotherapy (17,22). However, curative treatment is still exceptional.…”

Section: Discussionmentioning

confidence: 99%

Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization

Claes¹,

Wesseling²,

Jeuken³

et al. 2008

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Glioblastomas are highly aggressive primary brain tumors. Curative treatment by surgery and radiotherapy is generally impossible due to the presence of diffusely infiltrating tumor cells. Furthermore, the blood-brain barrier (BBB) in infiltrative tumor areas is largely intact, and this hampers chemotherapy as well. The occurrence of angiogenesis in these tumors makes these tumors attractive candidates for antiangiogenic therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization

Claes¹,

Wesseling²,

Jeuken³

et al. 2008

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…Further molecular analysis showed a 46% 2‐year survival in a favorable subset of patients with epigenetic silencing of the O 6 ‐methylguanine‐DNA methyltransferase DNA‐repair gene. ( 13 – 15 ) …”

Section: Introductionmentioning

confidence: 99%

Intensity modulated radiation therapy versus three‐dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison

MacDonald

Ahmad

Kachris

et al. 2007

J Applied Clin Med Phys

View full text Add to dashboard Cite

The present study compared the dosimetry of intensity‐modulated radiation therapy (IMRT) and three‐dimensional conformal radiation therapy (3D‐CRT) techniques in patients treated for high‐grade glioma. A total of 20 patients underwent computed tomography treatment planning in conjunction with magnetic resonance imaging fusion. Prescription dose and normal‐tissue constraints were identical for the 3D‐CRT and IMRT plans. The prescribed dose was 59.4 Gy delivered at 1.8 Gy per fraction using 4 – 10 MV photons. Normal‐tissue dose constraints were 50 – 54 Gy for the optic chiasm and nerves, and 55 – 60 Gy for the brainstem.The IMRT plan yielded superior target coverage as compared with the 3D‐CRT plan. Specifically, minimum and mean planning target volume cone down doses were 54.52 Gy and 61.74 Gy for IMRT and 50.56 Gy and 60.06 Gy for 3D‐CRT (p≤0.01). The IMRT plan reduced the percent volume of brainstem receiving a dose greater than 45 Gy by 31% (p=0.004) and the percent volume of brain receiving a dose greater than 18 Gy, 24 Gy, and 45 Gy by 10% (p=0.059), 14% (p=0.015), and 40% (p≤0.0001) respectively. With IMRT, the percent volume of optic chiasm receiving more than 45 Gy was also reduced by 30.40% (p=0.047). As compared with 3D‐CRT, IMRT significantly increased the tumor control probability (p≤0.005) and lowered the normal‐tissue complication probability for brain and brainstem (p<0.033).Intensity‐modulated radiation therapy improved target coverage and reduced radiation dose to the brain, brainstem, and optic chiasm. With the availability of new cancer imaging tools and more effective systemic agents, IMRT may be used to intensify tumor doses while minimizing toxicity, therefore potentially improving outcomes in patients with high‐grade glioma.PACs number: 87.53 Tf

show abstract

“…Outros autores preconizam que a combinação da radioterapia e quimioterapia com PCV é presumivelmente superior a qualquer terapia isolada 48 . Um estudo recente mostra que, embora os oligodendrogliomas sejam tumores sensíveis à quimioterapia, essa terapêutica adjuvante clássica não melhora a sobrevida nos pacientes com oligodendroglioma anaplásico recorrente 51 . Veninga e cols.…”

Section: Discussionunclassified

“…A caracterização das alterações genéticas desses tumores 49 (figura 1) promete ser tão importante quanto os achados histológicos e os fatores clínicos na definição da terapia apropriada 54 . Especificamente, diversos estudos têm confirmado que a deleção dos cromossomos 1p e 19q está associada com o fenótipo desses tumores e com a longa sobrevida sem recorrência após radioterapia e/ou quimioterapia 51 .…”

Section: Introductionunclassified

Untitled

2007

Arquivos Brasileiros de Neurocirurgia: Brazilian Neurosurgery

View full text Add to dashboard Cite

show abstract

Recent developments in the use of chemotherapy in brain tumours

Cited by 109 publications

References 60 publications

Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization

Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization

Intensity modulated radiation therapy versus three‐dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison

Untitled

Contact Info

Product

Resources

About